File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models

TitleDevelopment of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models
Authors
Okada, MOkuno, YHashimoto, SKita, YKanamaru, NNishida, YTsunai, YInoue, RNakatani, HFukamizu, RNamie, YYamada, JTakao, KAsai, RAsaki, RKase, TTakemoto, YYoshida, SPeiris, JSMChen, PJYamamoto, NNomura, TIshida, IMorikawa, STashiro, MSakatani, M
KeywordsHuman neutralizing antibody against M
SARS DNA vaccine
SCID-PBL/hu
Issue Date2007
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2007, v. 25 n. 16 SPEC. ISS., p. 3038-3040 How to Cite?
DOI: http://dx.doi.org/10.1016/j.vaccine.2007.01.032
AbstractWe have investigated novel vaccine strategies against severe acute respiratory syndrome (SARS) CoV using cDNA constructs encoding the structural antigens: (S), (M), (E), or (N) protein, derived from SARS CoV. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain disrupted SCID mice, and SCID-PBL/hu mice were constructed. These mice can be used to analyze the human immune response in vivo. SARS M DNA vaccine and N DNA vaccine induced human CTL specific for SARS CoV antigens. Alternatively, SARS M DNA vaccines inducing human neutralizing antibodies and human monoclonal antibodies against SARS CoV are now being developed. These results show that these vaccines can induce virus-specific immune responses and should provide a useful tool for development of protective and therapeutic vaccines. © 2007 Elsevier Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/79032
ISSN
0264-410X
2021 Impact Factor: 4.169
2020 SCImago Journal Rankings: 1.585
ISI Accession Number ID
WOS:000246095400014
References
References in Scopus

 

DC FieldValueLanguage
dc.contributor.authorOkada, Men_HK
dc.contributor.authorOkuno, Yen_HK
dc.contributor.authorHashimoto, Sen_HK
dc.contributor.authorKita, Yen_HK
dc.contributor.authorKanamaru, Nen_HK
dc.contributor.authorNishida, Yen_HK
dc.contributor.authorTsunai, Yen_HK
dc.contributor.authorInoue, Ren_HK
dc.contributor.authorNakatani, Hen_HK
dc.contributor.authorFukamizu, Ren_HK
dc.contributor.authorNamie, Yen_HK
dc.contributor.authorYamada, Jen_HK
dc.contributor.authorTakao, Ken_HK
dc.contributor.authorAsai, Ren_HK
dc.contributor.authorAsaki, Ren_HK
dc.contributor.authorKase, Ten_HK
dc.contributor.authorTakemoto, Yen_HK
dc.contributor.authorYoshida, Sen_HK
dc.contributor.authorPeiris, JSMen_HK
dc.contributor.authorChen, PJen_HK
dc.contributor.authorYamamoto, Nen_HK
dc.contributor.authorNomura, Ten_HK
dc.contributor.authorIshida, Ien_HK
dc.contributor.authorMorikawa, Sen_HK
dc.contributor.authorTashiro, Men_HK
dc.contributor.authorSakatani, Men_HK
dc.date.accessioned2010-09-06T07:49:46Z-
dc.date.available2010-09-06T07:49:46Z-
dc.date.issued2007en_HK
dc.identifier.citationVaccine, 2007, v. 25 n. 16 SPEC. ISS., p. 3038-3040en_HK
dc.identifier.issn0264-410Xen_HK
dc.identifier.urihttp://hdl.handle.net/10722/79032-
dc.description.abstractWe have investigated novel vaccine strategies against severe acute respiratory syndrome (SARS) CoV using cDNA constructs encoding the structural antigens: (S), (M), (E), or (N) protein, derived from SARS CoV. PBL from healthy human volunteers were administered i.p. into IL-2 receptor γ-chain disrupted SCID mice, and SCID-PBL/hu mice were constructed. These mice can be used to analyze the human immune response in vivo. SARS M DNA vaccine and N DNA vaccine induced human CTL specific for SARS CoV antigens. Alternatively, SARS M DNA vaccines inducing human neutralizing antibodies and human monoclonal antibodies against SARS CoV are now being developed. These results show that these vaccines can induce virus-specific immune responses and should provide a useful tool for development of protective and therapeutic vaccines. © 2007 Elsevier Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccineen_HK
dc.relation.ispartofVaccineen_HK
dc.rightsVaccine. Copyright © Elsevier Ltd.en_HK
dc.subjectHuman neutralizing antibody against Men_HK
dc.subjectSARS DNA vaccineen_HK
dc.subjectSCID-PBL/huen_HK
dc.titleDevelopment of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse modelsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0264-410X&volume=25&issue=16&spage=3038&epage=40&date=2007&atitle=Development+of+vaccines+and+passive+immunotherapy+against+SARS+corona+virus+using+SCID-PBL/hu+mouse+modelsen_HK
dc.identifier.emailPeiris, JSM: malik@hkucc.hku.hken_HK
dc.identifier.authorityPeiris, JSM=rp00410en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2007.01.032en_HK
dc.identifier.pmid17289225-
dc.identifier.scopuseid_2-s2.0-84984585886en_HK
dc.identifier.hkuros134616en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-34047096805&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume25en_HK
dc.identifier.issue16 SPEC. ISS.en_HK
dc.identifier.spage3038en_HK
dc.identifier.epage3040en_HK
dc.identifier.isiWOS:000246095400014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridOkada, M=8247382100en_HK
dc.identifier.scopusauthoridOkuno, Y=7202193504en_HK
dc.identifier.scopusauthoridHashimoto, S=8208749500en_HK
dc.identifier.scopusauthoridKita, Y=35237454300en_HK
dc.identifier.scopusauthoridKanamaru, N=8247380300en_HK
dc.identifier.scopusauthoridNishida, Y=16175790500en_HK
dc.identifier.scopusauthoridTsunai, Y=16176649600en_HK
dc.identifier.scopusauthoridInoue, R=55256899800en_HK
dc.identifier.scopusauthoridNakatani, H=16175750500en_HK
dc.identifier.scopusauthoridFukamizu, R=8315350800en_HK
dc.identifier.scopusauthoridNamie, Y=16175758000en_HK
dc.identifier.scopusauthoridYamada, J=16177025700en_HK
dc.identifier.scopusauthoridTakao, K=16176404700en_HK
dc.identifier.scopusauthoridAsai, R=16174217900en_HK
dc.identifier.scopusauthoridAsaki, R=16174116200en_HK
dc.identifier.scopusauthoridKase, T=7005279800en_HK
dc.identifier.scopusauthoridTakemoto, Y=35238734900en_HK
dc.identifier.scopusauthoridYoshida, S=35458480200en_HK
dc.identifier.scopusauthoridPeiris, JSM=7005486823en_HK
dc.identifier.scopusauthoridChen, PJ=7408354514en_HK
dc.identifier.scopusauthoridYamamoto, N=7403608342en_HK
dc.identifier.scopusauthoridNomura, T=54409213700en_HK
dc.identifier.scopusauthoridIshida, I=18344116900en_HK
dc.identifier.scopusauthoridMorikawa, S=7102226341en_HK
dc.identifier.scopusauthoridTashiro, M=7201482415en_HK
dc.identifier.scopusauthoridSakatani, M=7006692689en_HK
dc.identifier.issnl0264-410X-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats